Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

SpringWorks Therapeutics, Inc. Common Stock (SWTX)

Biological Products, (no Disgnostic Substances)

https://www.springworkstx.com

SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.

100 WASHINGTON BOULEVARD
STAMFORD, CT

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

09/13/2019

Market Cap

2,713,935,420

Shares Outstanding

72,060,000

Weighted SO

72,061,635

Total Employees

N/A

Upcoming Earnings

08/07/2024

Similar Tickers

RLAY --.--%

STOK --.--%

PLRX --.--%

BDTX --.--%

ARVN --.--%

DAWN --.--%

MRTX --.--%

AMLX --.--%

TERN --.--%

Beta

0.7800

Last Div

0.0000

Range

18.0-53.92

Chg

0.3300

Avg Vol

834858

Mkt Cap

2713935420

Exch

NASDAQ

Country

US

Phone

203 883 9490

DCF Diff

34.2615

DCF

2.4585

Div Yield

0.0000

P/S

29.5726

EV Multiple

-8.2869

P/FV

4.8648

Div Yield %

0.0000

P/E

-8.9961

PEG

46.2398

Payout

0.0000

Current Ratio

7.9142

Quick Ratio

7.7726

Cash Ratio

1.4660

DSO

97.4585

DIO

395.6003

Op Cycle

493.0588

DPO

404.3653

CCC

88.6936

Gross Margin

0.9224

Op Margin

-3.5012

Pretax Margin

-3.2806

Net Margin

-3.2806

Eff Tax Rate

0.0351

ROA

-0.4877

ROE

-0.5613

ROCE

-0.5709

NI/EBT

1.0000

EBT/EBIT

0.9370

EBIT/Rev

-3.5012

Debt Ratio

0.0114

D/E

0.0127

LT Debt/Cap

0.0108

Total Debt/Cap

0.0125

Int Coverage

-75.0909

CF/Debt

-33.1330

Equity Multi

1.1089

Rec Turnover

3.7452

Pay Turnover

0.9026

Inv Turnover

0.9226

FA Turnover

3.7356

Asset Turnover

0.1487

OCF/Share

-3.1555

FCF/Share

-3.3460

Cash/Share

5.1792

OCF/Sales

-2.5486

FCF/OCF

1.0604

CF Coverage

-33.1330

ST Coverage

-244.1399

CapEx Coverage

-16.5618

Div&CapEx Cov

-16.5618

P/BV

4.8648

P/B

4.8648

P/S

29.5726

P/E

-8.9961

P/FCF

-10.9429

P/OCF

-11.5799

P/CF

-11.5799

PEG

46.2398

P/S

29.5726

EV Multiple

-8.2869

P/FV

4.8648

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 15, 19:46 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPOF, PRA, SWTX on Behalf of Shareholders GlobeNewswire Inc. Jun 15, 18:44 HAPPY FATHER’S DAY and $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: OPOF, PRA, SWTX and FLS GlobeNewswire Inc. Jun 02, 23:14 $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger – PRA, AXL, SWTX and VIGL Benzinga Jun 01, 23:42 $HAREHOLDER NOTICE: The M&A Class Action Firm Continues To Investigate The Merger - PRA, AXL, SWTX and VIGL GlobeNewswire Inc. May 24, 23:17 SpringWorks Therapeutics erhält positive CHMP-Stellungnahme für Mirdametinib zur Behandlung erwachsener und pädiatrischer Patienten mit NF1-PN GlobeNewswire Inc. May 24, 23:17 SpringWorks Therapeutics krijgt positief advies van de CHMP voor Mirdametinib voor de behandeling van volwassen en pediatrische patiënten met NF1-PN GlobeNewswire Inc. May 24, 23:17 SpringWorks Therapeutics reçoit un avis favorable du CMUH pour l’utilisation du mirdamétinib pour le traitement des patients adultes et pédiatriques atteints de NF1-PN GlobeNewswire Inc. May 24, 23:17 SpringWorks Therapeutics recibe un dictamen positivo del CHMP para el uso de mirdametinib en el tratamiento de la NF1-NP en pacientes adultos y pediátricos GlobeNewswire Inc. May 24, 23:17 SpringWorks Therapeutics: CHMP valuta positivamente Mirdametinib per il trattamento di pazienti adulti e pediatrici affetti da NF1-PN GlobeNewswire Inc. May 18, 22:42 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWTX, NVEE, CHTR, INZY on Behalf of Shareholders GlobeNewswire Inc. May 18, 22:41 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AXL, KRON, PRA, SWTX on Behalf of Shareholders GlobeNewswire Inc. May 17, 17:00 $HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – PRA, KRON, AXL, SWTX Benzinga May 16, 22:30 STOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The Merger - PRA, KRON, AXL, SWTX GlobeNewswire Inc. Feb 12, 01:20 UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN GlobeNewswire Inc. Jan 08, 06:30 SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. Dec 05, 00:32 SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock GlobeNewswire Inc. Dec 05, 00:32 SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock GlobeNewswire Inc. Dec 05, 00:32 SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock GlobeNewswire Inc. Dec 05, 00:32 SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock MarketWatch Nov 28, 11:06 SpringWorks stock on track for record gain after FDA approves first treatment for rare type of aggressive tumors

Revenue Product Segmentation